ScholarIQanswers from OpenAlex & ORCID
James L. Abbruzzese
ResearcherPublications, citations & collaboration network
James L. Abbruzzese is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does James L. Abbruzzese have?
ScholarIQindexed works
James L. Abbruzzese has 780 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does James L. Abbruzzese have?
ScholarIQcitation count
James L. Abbruzzese has 59,202 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of James L. Abbruzzese?
ScholarIQh-index
James L. Abbruzzese has an h-index of 129 in OpenAlex.
What is the i10-index of James L. Abbruzzese?
ScholarIQi10-index
James L. Abbruzzese has an i10-index of 448 in OpenAlex.
What is the ORCID of James L. Abbruzzese?
ScholarIQorcid
The ORCID for James L. Abbruzzese is on the source record.
What is the OpenAlex record for James L. Abbruzzese?
ScholarIQopenalex
The OpenAlex for James L. Abbruzzese is on the source record.
What are the most-cited papers on James L. Abbruzzese?
ScholarIQmost cited works
Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of <i>TWIST</i> Gene Expression
Hui‐Wen Lo, Sheng-Chieh Hsu, Weiya Xia, Xinyu Cao, Jin‐Yuan Shih, Yongkun Wei, James L. Abbruzzese, Gabriel N. Hortobágyi, Mien‐Chie Hung
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.
Christiane J. Bruns, Carmen C. Solórzano, Matthew T. Harbison, Shutaro Ozawa, Rachel Tsan, Dominic Fan, James L. Abbruzzese, Peter Traxler, Elisabeth Buchdunger, Robert Radinsky, Isaiah J. Fidler
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Scott Kopetz, Paulo M. Hoff, Jeffrey S. Morris, Robert A. Wolff, Cathy Eng, Katrina Y. Glover, R. Adinin, Michael J. Overman, V VALERO, Sijin Wen, Christopher H. Lieu, Shaoyu Yan, Hai T. Tran, Lee M. Ellis, James L. Abbruzzese, John V. Heymach
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Christiane J. Bruns, Matthew T. Harbison, Darren W. Davis, Charles A. Portera, Rachel Tsan, David J. McConkey, Douglas B. Evans, James L. Abbruzzese, Daniel J. Hicklin, Robert Radinsky
Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma.
Peter W. T. Pisters, James L. Abbruzzese, Nora A. Janjan, Karen R. Cleary, Chusilp Charnsangavej, M.S. Goswitz, Tyvin A. Rich, Isaac Raijman, Robert A. Wolff, Renato Lenzi, J E Lee, Douglas B. Evans